BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 29756233)

  • 1. A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.
    Martínez-Terroba E; Behrens C; de Miguel FJ; Agorreta J; Monsó E; Millares L; Sainz C; Mesa-Guzman M; Pérez-Gracia JL; Lozano MD; Zulueta JJ; Pio R; Wistuba II; Montuenga LM; Pajares MJ
    J Pathol; 2018 Aug; 245(4):421-432. PubMed ID: 29756233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging.
    Martínez-Terroba E; Behrens C; Agorreta J; Monsó E; Millares L; Felip E; Rosell R; Ramirez JL; Remirez A; Torre W; Gil-Bazo I; Idoate MA; de-Torres JP; Pio R; Wistuba II; Pajares MJ; Montuenga LM
    Thorax; 2019 Apr; 74(4):371-379. PubMed ID: 30472670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
    Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
    Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a nomogram with an epigenetic signature for predicting survival in patients with lung adenocarcinoma.
    Wang J; He L; Tang Y; Li D; Yang Y; Zeng Z
    Aging (Albany NY); 2020 Nov; 12(22):23200-23216. PubMed ID: 33221751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators.
    Rakha E; Pajares MJ; Ilie M; Pio R; Echeveste J; Hughes E; Soomro I; Long E; Idoate MA; Wagner S; Lanchbury JS; Baldwin DR; Hofman P; Montuenga LM
    Eur J Cancer; 2015 Sep; 51(14):1897-903. PubMed ID: 26235745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
    Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
    Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma.
    Qian F; Yang W; Wang R; Xu J; Wang S; Zhang Y; Jin B; Yu K; Han B
    J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1227-1235.e2. PubMed ID: 29223834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the 8th Edition of the UICC-TNM Classification on Clinical Stage 0-IA Lung Adenocarcinoma: Does the New Classification Predict Postoperative Prognosis More Precisely than the Previous One?
    Wang L; Anraku M; Sato M; Nitadori JI; Nagayama K; Kitano K; Nakajima J
    Ann Thorac Cardiovasc Surg; 2018 Oct; 24(5):223-229. PubMed ID: 29848840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.
    Warth A; Muley T; Meister M; Stenzinger A; Thomas M; Schirmacher P; Schnabel PA; Budczies J; Hoffmann H; Weichert W
    J Clin Oncol; 2012 May; 30(13):1438-46. PubMed ID: 22393100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A gene expression-based single sample predictor of lung adenocarcinoma molecular subtype and prognosis.
    Liljedahl H; Karlsson A; Oskarsdottir GN; Salomonsson A; Brunnström H; Erlingsdottir G; Jönsson M; Isaksson S; Arbajian E; Ortiz-Villalón C; Hussein A; Bergman B; Vikström A; Monsef N; Branden E; Koyi H; de Petris L; Patthey A; Behndig AF; Johansson M; Planck M; Staaf J
    Int J Cancer; 2021 Jan; 148(1):238-251. PubMed ID: 32745259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
    Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer.
    Liu K; Chen HL; Gu MM; You QS
    Int J Clin Exp Pathol; 2015; 8(12):16081-8. PubMed ID: 26884885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.
    Bao X; Shi R; Zhao T; Wang Y
    J Mol Med (Berl); 2020 Jun; 98(6):805-818. PubMed ID: 32333046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.
    Kratz JR; Haro GJ; Cook NR; He J; Van Den Eeden SK; Woodard GA; Gubens MA; Jahan TM; Jones KD; Kim IJ; He B; Jablons DM; Mann MJ
    J Thorac Oncol; 2019 Jul; 14(7):1223-1232. PubMed ID: 30959120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of a Methylome-based Malignancy Density Scoring System to predict recurrence risk in early-stage Lung Adenocarcinoma.
    Yang L; Zhang J; Yang G; Xu H; Lin J; Shao L; Li J; Guo C; Du Y; Guo L; Li X; Han-Zhang H; Wang C; Chuai S; Ye J; Kang Q; Liu H; Ying J; Wang Y
    Theranostics; 2020; 10(17):7635-7644. PubMed ID: 32685009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer.
    Gentles AJ; Bratman SV; Lee LJ; Harris JP; Feng W; Nair RV; Shultz DB; Nair VS; Hoang CD; West RB; Plevritis SK; Alizadeh AA; Diehn M
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26286589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
    He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
    Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of distant recurrence in resected stage I and II lung adenocarcinoma.
    Aramini B; Casali C; Stefani A; Bettelli S; Wagner S; Sangale Z; Hughes E; Lanchbury JS; Maiorana A; Morandi U
    Lung Cancer; 2016 Nov; 101():82-87. PubMed ID: 27794412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
    Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB
    Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.